BioWorld

Sep. 23, 2003

BioMarin Stops Development Of Neutralase In CABG Surgery

Officials at BioMarin Inc. believe themselves to be fortunate in determining fairly early that their lead product, Neutralase, probably won't make it to market. (BioWorld Today) Read More

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Controversy Smolders As To U.S. Regions Of Lyme Disease, Borrelia burgdorferi, Despite M.D. Practices

First-Round Financing Of $12.5M Puts Ambrx On Development Path

Genzyme Invests $37.7M In CAT As Companies Restructure Pact

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 20, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

Novel caspase-2 inhibitor shows in vivo neuroprotective effects

BioWorld Science

Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...